Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0828 Triumvira series A
BioCentury & Getty Images

Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

A decision to stall a blood cancer program in favor of solid tumors helped drive investor interest

A decision to stall a blood cancer program in favor of solid tumors helped drive investors interest.

Aug 28, 2020 | 9:04 PM GMT

Since its 2015 launch, Triumvira has changed CEOs once, developed a third iteration of its engineered T cell therapeutics platform, and deprioritized a former lead

Read the full 820 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE